Herbal drug usage with modern medicine 1: Case study of an enzyme inducer, St John’s Wort – Some perspectives
DOI:
https://doi.org/10.22377/ijgp.v2i4.1Abstract
While the usage of herbal medicines continues to be on the rise, it brings along an imminent risk of drug-drug interaction with scoresof modern day medicine(s). Th e focus of this article is to provide an overview of a potential drug-drug interaction resulting, due to
induction of cytochrome P450 enzyme(s) and/or transporters, from the use of a popular herbal product known as St. John’s Wort (SJW)
with modern day medicines. Also, it provides some perspectives and considerations in rationalizing the use of SJW.
Key words: Cytochrome P450, induction, interaction, P-glycoprotein, pharmacokinetics, St. John’s Wort
Downloads
References
Man SC, Durairajan SS, Kum WF, Lu JH, Huang JD, Cheng CF, et
al. Systematic review on the effi cacy and safety of herbal medicines
for AlzheimerÂ’s disease. J Alzheimers Dis 2008;14:209-23.
Armstrong TS, Gilbert MR. Use of complementary and alternative
medical therapy by patients with primary brain tumours. Curr
Neurol Neurosci Rep 2008;8:264-8.
Burgess JA, van der Ven PF, Martin M, Sherman J, Haley J. Review
of over-the-counter treatments for apthous ulceration and results
from use of a dissolving over patch containing glycyrrhiza complex
herbal extract. J Contemp Dent Pract 2008;9:88-98.
Wang E, Wylie-Rosett J. Review of selected Chinese herbal
medicines in the treatment of type-2 diabetes. Diabetes Educ
;34:645-54.
van der Watt G, Laugharne J, Janca A. Complementary and
alternative medicine in the treatement of anxiety and depression.
Curr Opin Psychiatr 2008;21:37-42.
Guo R, Pitt ler MH, Ernst E. Herbal medicines for the treatment
of allergic rhinitis: A systematic review. Ann Allergy Asthma
Immunol 2007;99:483-95.
Ioannides C. Drug-phytochemical interactions. Inß ammopharmacol
;11:7-42.
Greeson JM, Sanford B, Moonti DA. St JohnÂ’s wort (Hypercium
perforatum): A review of the current pharmacological, toxicological,
and clinical literature. Pyschopharmacol (Berl) 2001;153:402-14.
Upton R. St Johns Wort – Hypercium perforatum. American Herbal
Pharmacopoeia – Americal Botanical Council 1996.
Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito
F, Parisi A, et al. Serotonin, norepinephrine and dopamine
involvement in the antidepressant action of hypericum perforatum.
Pharmacopsych iatry 2001;34:45-9.
Kleber E, Obry T, Hippeli S, Schneider W, Elstner EF.
Biochemical activities of extracts from Hypericum perforatum.
Arzneimitt elforsch ung 1999;49:106-9.
Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer
C. Hyperforin represents the neurotransmitt er reuptake inhibiting
constituent of hypericum extract. Pharmacopsych iatry 1998;31:
-21.
Chatt erjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant
activity of hypericum perforatum and hyperforin: the neglected
possibility. Pharmacopsychiatry 1998;31:7-15.
Singer A, Wonnemann M, Muller WE. Hyperforin, a major
antidepressant constituent of St. John’s wort, inhibits serotonin
uptake by elevating free intracellular Na+11. J Pharmacol Exp
Ther 1999;290:1363-8.
Vorbach EU, Arnoldt KH, Hubner WD. Effi cacy and tolerability of
St. JohnÂ’s wort extract LI 160 versus imipramine in patients with
severe depressive episodes according to ICD-10. Pharmacopschiatr
;30:81-5.
Gupta RK, Moller HJ. St. JohnÂ’s Wort: An option for the primary
care treatment of depressive patients? Eur Arch Psychiatr Clin
Neurosci 2003;253:140-8.
Tedeschi E, Menegazzi M, Margott o D, Suzuki H, Forestermann U,
Kleiner H. Anti-inß ammatory actions of St. John’s wort: Inhibition
of human inducible nitric-oxide synthase expression by downregulating
signal transducer and activator of transcription-1-alpha
(STAT-alpha) activation. J Pharmacol Exp Ther 2003;307:254-61.
Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin
a constituent of St. JohnÂ’s Wort (Hypercium perforatum) extract
induces apoptosis by triggering activation of caspases and with
hypericin synergistically exerts cytotoixicity towards human
malignant cell lines. Eur J Pharm Biopharm 2003;56:123-32.
Sch empp CM, Kirkin V, Simmon-Haarhaus B, Kersten A, Kiss J,
Termeer CC, et al. Inhibition of tumour cell growth by hyperforin,
a novel anticancer drug from St. JohnÂ’s wort that acts by induction
of apoptosis. Oncogene 2003;21:1242-50.
Schempp CM, Pelz K, Witt mer A, Schopf E, Simon JC. Antibacterial
activity of hyperforin from St JohnÂ’s wort, against multiresistant
Staphylococcus aureus and gram-positive bacteria. Lancet
;353:2129.
Whitt en DL, Myers SP, Hawrelak JA, Wohlmuth H. The eff ect of St
JohnÂ’s wort extracts on CYP3A: A systematic review of prospective
clinical trials. Br J Clin Pharmacol 2006;62:512-26.
Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S,
Mundkowski RG, Miekisch W, et al. The extent of induction of
CYP3A by St. JohnÂ’s wort varies among products and is linked to
hyperforin dose. Eur J Clin Pharmacol 2006;62:29-36.
Wenk M, Todesco L, Krahenbuhl S. Eff ect of St JohnÂ’s Wort on
the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase
, and xanthine oxidase in healthy males and females. Br J Clin
Pharmacol 2004;57:495-9.
Mathijssen RH, Verweij J, Bruijn P, Loos WJ, Sparreboom A.
Eff ects of St JohnÂ’s wort on irinotecan metabolism. J Nat Cancer
Inst 2002;94:1247-9.
Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez
A, Gomez-Mateos J, Leon-Jimenez E, et al. Pharmacokinetic
interactions between efavirenz and rifampicin in HIV-infected
patients with tuberculosis. Clin Pharmacokinet 2002;41:681-90.
James JS. St JohnÂ’s wort warning: do not combine with protease
inhibitors, NNRTIs. AIDS Treat News 2000;337:3-5.
Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Fallon J. Indinavir
concentrations and St JohnÂ’s wort. Lancet 2000;355:547-8.
Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4,
P-gycoprotein, and serum protein binding to the intestinal
first-pass extraction of saquinavir. J Pharmacol Exp Ther
;308:941-8.
Fromm MF, Busse D, Niedergesass S, Vogelgesang B, Eichelbaum
M. The eff ect of prehepatic and hepatic metabolism of verapamil
by rifampin. Hepatol 1996;24:796-801.
Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U,
Lennernas H. St JohnÂ’s wort decreases the bioavailability of R- and
S-verapamil through induction of the Þ rst pass metabolism. Clin
Pharmacol Ther 2004;75:298-309.
Markowitz JS, De Vane CL, Boulton DW, Carson SW, Nahas Z,
Risch SC. Eff ect of St. JohnÂ’s wort (Hypercium perforatum) on
cythochrome P4502D6 and 3A4 activity in healthy volunteers.
Life Sci 2000;66:133-9.
Johne A, Brockmoller J, Bauer S, Mauer A, Lanheinrich M, Roots
I. Pharmacokinetic interaction of digoxin with an herbal extract
from St. JohnÂ’s wort (Hypercium perforatum). Clin Pharmacol
Ther 1999;66:338-45.
Greiner B, Eich elbaum M, Fritz P, Kreich gauer HP, von Rich ter
O, Zundler J, et al. The role of intestinal P-glycoprotein in the
interaction of digoxin and rifampin. J Clin Invest 1999;104:
-53.
Humman MA, Craven R, Bruce MA, Haehner-Daniels BD, Hall
SD. The eff ects of rifampinÂ’s administration on the disposition of
fexofenadine. Clin Pharmacol Ther 2001;69:114-21.
Markowitz JS, Donovan JL, De Vane CL, Taylor RM, Ruan Y, Wang
JS, et al. Eff ect of St JohnÂ’s wort on drug metabolism by induction
of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
Johne A, Sch mider J, Brock moller J, Stadelmann AM, Stormer
E, Bauer S, et al. Decreased plasma levels of amitriptyline and
its metabolites on comedication with an extract from St JohnÂ’s
wort (Hypercium perforatum). J Clin Psychopharmacol 2002;22:
-54.
Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer
HH, et al. Alterations in cyclosporine A pharmacokinetics and
metabolism with St JohnÂ’s Wort in renal transplant patients. B J
Clin Pharmacol 2003;55:203-11.
Mueller SC, Uehleke B, Woehling H, Petzsch M, Majch er-Peszynska
J, Hehl EM, et al. Eff ect of St JohnÂ’s wort dose and preparations
on the pharmacokinetics of digoxin. Clin Pharmacol Ther
;75:546-7.
Smith P. The inß uence of St John’s wort on the pharmacokinetics
and protein binding of imatinib mesylate, Pharmacother
;24:1508-14.
Frye RF, Fitzgerald SM, Lagatt uta TF, Hruska MW, Egorin MJ.
Eff ect of St JohnÂ’s wort on imatinbib mesylate pharmacokinetics.
Clin Pharmacol Ther 2004;76:323-9.
Sch warz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser
H, et al. Induction of intestinal P-glycoprotein by St. JohnÂ’s wort
reduces the oral bioavailability of talinolol. Clin Pharmacol Ther
;81:669-78.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD,
Duke CC, et al. Eff ect of St JohnÂ’s wort and gingseng on the
pharmacokinetics and pharmacodynamics of warfarin in healthy
subjects. Br J Clin Pharmacol 2004;57:592-9.
